

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039351 A2

(51) International Patent Classification⁷: **A61K 9/00**

(21) International Application Number:
PCT/EP2003/012180

(22) International Filing Date: 31 October 2003 (31.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2002A002323 31 October 2002 (31.10.2002) IT

(71) Applicants and

(72) Inventors: GASCO, Maria, Rosa [IT/IT]; Lungo Po
Antonelli, 207, I-10153 Torino (IT). ZARA, Gian, Paolo
[IT/IT]; Corso Trapani, 207, I-10100 Torino (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SAETTONE, Marco,
Fabrizio [IT/IT]; Via G. Giusti, 24, I-55049 Viareggio (IT).

(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi
S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE TREATMENT OF OPHTHALMIC DISEASES

(57) Abstract: Pharmaceutical compositions for the treatment of ophthalmic diseases, suitable for topical ocular administration and for systemic administration, comprising solid lipid nanoparticles (SLNs) with a mean diameter comprised between 50 and 400 nm wherein, within said nanoparticles, a pharmacologically active substance for the specific ophthalmic treatment is incorporated.

Pharmaceutical compositions suitable for the treatment of ophthalmic diseases

Known art

Historically, the therapeutic treatment of the eye has been essentially directed
5 towards the administration of drugs directly to the tissues and the fluids of the anterior segment of the eye.

Only recently has research been directed towards the administration of drugs intended for the posterior segment of the eye (uveal region, vitreous fluid, choroid and retina).

10 The eye is an isolated and highly protected organ.

In particular, the tight junctional complexes of the retinal pigmented epithelium and the retinal capillaries constitute the blood-retinal barrier for which the systemic administration of drugs does not succeed in reaching an adequate level within the posterior segment of the eye.

15 On the other hand, even with topical administration, only small amounts of drug reach the retina, as penetration through the external walls of the eye is very low.

Nevertheless, there are numerous pathologies of the posterior segment of the eye which require pharmacological treatment such as for example bacterial or fungal endophthalmitis, viral retinitis, vitreoretinopathy, toxoplasmosis, uveitis, tumours,
20 vascular diseases, diabetic retinopathy, age-related macular degeneration, glaucoma and others.

In order to overcome such difficulties, various methods of administration have been investigated.

Some authors have intravenously injected thermosensitive liposomes which have
25 been lysed within the retinal vessels using microwave generated impulses (Khoobehi B. *et al.* Ophthalmology 1988 Jul, 95 (7): 950-5).

The injection of drugs into the vitreous fluid has also been described (Martidis A. *et al.* Ophthalmology 2002, 195 (5): 920-7).

However, frequently, this injection must be repeated and furthermore, can hold
30 dangerous complications for the structures of the eye.

Finally, slow-release ocular implants have been proposed, such as for example Vitrasert®, an implant which is surgically inserted into the eye and releases

ganciclovir over a period of six months. (Morley MG. *et al* Ophthalmology 1996; 103 (10): 1517).

From that reported above, it is clearly evident that only through very complicated, time consuming and expensive methods, is it possible to convey drugs to the

5 posterior segment of the eye.

Summary

Now, pharmaceutical compositions suitable for the treatment of ophthalmic diseases have been found that allow to overcome the difficulties of the known art.

10 Said compositions comprise solid lipidic nanoparticles (SLNs) having mean diameter comprised between 50 and 400 nm and preferably comprised between 100 and 200 nm wherein, within said nanoparticles, a pharmacologically active substance for the specific ophthalmic treatment is incorporated.

Said compositions are prepared both in a form suitable for intravenous administration and a form suitable for topical ocular applications.

15 It has been found that the solid lipidic nanoparticles of the present invention are able to transport the drug to the vitreous fluid and to the retina, through the above mentioned administration routes, overcoming the difficulties of the known art.

Detailed description of the invention

20 The present invention refers to the use of solid lipidic nanoparticles (SLNs) for the preparation of pharmaceutical compositions suitable for the treatment of ophthalmic diseases.

A pharmacologically active substance for the specific ophthalmic treatment is incorporated within said nanoparticles.

25 The nanoparticles containing the pharmacologically active substance are prepared essentially according to the process described in European patent N° 0526666 which comprises the following steps:

- a) a molten lipid substance containing a drug or a complex thereof is mixed with a mixture comprising, and preferably consisting of water, a surfactant, a cosurfactant and optionally a counterion of the drug, pre-warmed to a
30 temperature at least equal to the melting temperature of said lipid substance, thus obtaining a microemulsion having a temperature at least equal to the melting temperature of said lipid substance;

b) the microemulsion obtained in step a) is dispersed in water or in an aqueous medium cooled to a temperature comprised of between 2 and 5 °C, thus obtaining a dispersion of solid lipidic nanoparticles incorporating the drug;

c) the dispersion obtained in step b) is washed with water or with an aqueous medium by diafiltration with the practically total elimination of the surfactant and cosurfactant;

d) the dispersion obtained as in step c) is dried by lyophilisation or by spray drying or by evaporation, thus obtaining the solid lipidic nanoparticles (SLNs) with the incorporated drug.

The microemulsion of step a) can be sterilised by filtration using sterilising filters. The dispersion obtained in step c) can be sterilised in an autoclave or by filtration using sterilising filters.

According to an alternative embodiment, the microemulsion obtained in step a) is added to a mixture comprising, and preferably consisting of, water, a surfactant, a cosurfactant and a lipid, warmed to a temperature at least equal to the melting temperature of the lipid and the mixture thus obtained is dispersed in water or in an aqueous medium cooled to a temperature comprised of between 2 and 5°C.

According to an additional alternative embodiment, at the end of step a) a substance suitable to sterically stabilise the lipidic nanoparticles is added.

The lipidic substances used in the process are selected from the group comprising:

- triglycerides, particularly trilaurine, tricaprilol, tristearine, tripalmitine, capric/caprylic triglycerides (Mygliol®, Captex® and Labrafac®);
- diglycerides, particularly dipalmitine and distearine;
- monoglycerides, particularly glyceryl monostearate (Myvapex 600®) and glyceryl palmitostearate (Precirol®);
- aliphatic alcohols, particularly cetyl alcohol and stearyl alcohol;
- fatty acids having C10 – C22 chains, decanoic acid, linoleic acid and polyalcohol esters thereof;
- cholesterol and esters thereof, particularly cholesteryl hemisuccinate, cholesteryl butyrate and cholesteryl palmitate.

The surfactants are selected from the group comprising:

- lecithins, as they are, such as Lipoid 75® and Epicuron 200®, phospholipids and hydrogenated forms thereof and synthetic and semi-synthetic derivatives thereof;
- bile salts, particularly sodium glycocholate, sodium taurocholate and taurodeoxycholate;
- Tween 20, Tween 40, Tween 80, Span 20, Span 40 and Span 60;
- emulsifiers, particularly gelatin.

The cosurfactants are selected from the group comprising:

- low molecular weight alcohols or glycols, particularly butanol, hexanol and hexadiol;
- low molecular weight fatty acids, particularly butyric acid and octanoic acid;
- phosphoric acid esters, benzylic alcohol and bile salts.

The substances suitable to sterically stabilise the lipidic nanoparticles are selected from dipalmitoyl phosphatidyl ethanolamine-PEG, diacyl phosphatidyl ethanolamine PEG (PEG M.W. 750-2000) and fatty acids pegylated with PEG-methylethers (PEG M.W. 750-2000).

The pharmacologically active substances suitable for the treatment of ophthalmic diseases according to the present invention can be both of the hydrophilic type and of the hydrophobic type and comprise antibiotics, antifungal agents, antiviral agents, antineoplastics, drugs for diabetic retinopathy, steroidal and non-steroidal anti-inflammatory agents, and antiglaucoma drugs. Preferably said pharmacologically active substances are selected from the group comprising: amphotericin, miconazole, ganciclovir, saquinavir, acyclovir, famciclovir, vidarabine, idoxuridine, β -interferon, paclitaxel, methotrexate, doxorubicin, angiopoietin 1, diclophenac, indomethacin, ketorolac, piroxicam, flurbiprofen, dexamethasone, triamcinolone, hydrocortisone, fluorometholone, rimexolone, timolol, betaxolol and acetazolamide.

The solid lipidic nanospheres (SLNs) of the present invention have a mean diameter comprised between 50 and 400 nm and preferably comprised between 100 and 200 nm and a polydispersion comprised between 0.06 and 0.30 and preferably comprised between 0.10 and 0.20.

Said SLNs have a pharmacologically active substance content comprised between

0.1 and 7.0 %.

They are used for the preparation of pharmaceutical compositions for intravenous administration or for topical ocular administration.

The compositions for intravenous administration are prepared by dispersion of the
5 SLNs in isotonic aqueous solutions in such quantities as to obtain a concentration of SLNs comprised between 10 and 250 mg/ml.

Preferably said aqueous solution is made isotonic by the addition of glycerol.

The compositions for topical ocular administration are prepared in the same manner with the further addition of 0.1-0.4% of a viscosizing substance, for
10 example polyvinyl alcohol or hydroxypropyl cellulose, and contain 1.0 to 25% w/v SLNs.

The present invention also refers to a therapeutic method for the treatment of ophthalmic diseases comprising, and preferably consisting in, the intravenous or topical ocular administration of a therapeutically effective amount of a
15 pharmaceutical composition as defined above.

The dosage for intravenous administration is of an amount of composition containing 0.01-5.0 milligrams of active substance per kilogram of body weight. The dosage for topical ocular administration is of an amount of composition containing 0.01-5.0 mg of active substance per eye.

20 The compositions according to the present invention have important advantages compared to the known art with regard to both the simplicity of preparation and application and the efficacy of the active substance.

Indeed they allow the transport of the SLNs to the posterior segment of the eye following both systemic and topical ocular administration.

25 In any case, the blood-retinal barrier is easily overcome and the active substance incorporated within the SLNs reaches the vitreous fluid and the retina.

It shall be noted that said compositions allow the transport across the blood-retinal barrier even of active substances that are practically insoluble in an aqueous medium.

30 Finally, the compositions for intravenous administration can be constituted by sterically stabilised SLNs as already observed, with the advantage of minimising their uptake by macrophages.

For the purpose of illustration of the preparation process of the solid lipidic nanoparticles, of the product obtained and of the effects of its ophthalmic administration, the following examples are reported.

Example 1 (Preparation of the SLNs)

- 5 200 mg of molten stearic acid at a temperature of 70°C containing a 1:2 gentamicin-hexadecylphosphate (28.85 mg, equivalent to 12 mg of gentamicin) complex are added to a mixture constituted by filtered water (2 ml), Epikuron 200® (105 mg) and sodium taurocholate (285 mg) warmed to a temperature of 70 °C. The microemulsion obtained, having a temperature of 70 °C, is dispersed in water
10 in a volume ratio of 1/5 at a temperature of 2-3°C by mechanical stirring obtaining a dispersion of solid lipidic nanoparticles (SLNs).

The dispersion obtained is washed twice with water for injection by diafiltration.

The SLNs have a mean diameter of 75 nm and a polydispersion of 0.2 and the lyophilised product has a gentamicin content of 3.3%.

15 Example 2 (intravenous administration)

An isotonic aqueous dispersion has been prepared with the solid lipidic nanoparticles (SLNs) prepared according to example 1, having a concentration of SLNs corresponding to 6 mg/ml of gentamicin.

- 20 The dispersion has been injected into the marginal ear vein of three male New Zealand albino rabbits having weights of 2.8-3.5 kg. The injected dose of gentamicin has been 1.5 mg/kg.

The commercial composition Gentomil®, containing the same dose of gentamicin, has been injected as a control into other three rabbits having the same characteristics.

- 25 One hour after administration, the following results, which represent the mean values of the gentamicin concentrations in various ocular areas, have been obtained.

(a) Dispersion of SLNs:

- concentration of gentamicin in the aqueous fluid:
30 right eye = 300 ng/100 µl
left eye = 326 ng/100 µl
- concentration of gentamicin in the vitreous fluid:

right eye = 499 ng/100 μ l

left eye = 531 ng/100 μ l

- concentration of gentamicin in the retina:

right eye = 1225 ng/100 μ l

5 left eye = 1365 ng/100 μ l

(b) Gentomil® composition

- Concentration of gentamicin in the aqueous fluid:

right eye = 50 ng/100 μ l

left eye = 56 ng/100 μ l

10 - Concentration of gentamicin in the vitreous fluid:

right eye = 3,5 ng/100 μ l

left eye = 2,5 ng/100 μ l

- Concentration of gentamicin in the retina: non perceptible.

Example 3 (intravenous administration)

15 Example 2 has been repeated with the difference that the dose injected has been 2 mg/kg.

Three hours after administration, the following results have been obtained.

(a) Dispersion of SLNs:

- concentration of gentamicin in the aqueous fluid:

20 right eye = 244 ng/100 μ l

left eye = 120 ng/100 μ l

- concentration of gentamicin in the vitreous fluid:

right eye = 126 ng/100 μ l

left eye = 157 ng/100 μ l

25 - concentration of gentamicin in the retina:

right eye = 99,5 ng/100 μ l

left eye = 84 ng/100 μ l

(b) Gentomil® composition

- Concentration of gentamicin in the aqueous fluid:

30 right eye = 40 ng/100 μ l

left eye = 36 ng/100 μ l

- Concentration of gentamicin in the vitreous fluid:
not perceptible
- Concentration of gentamicin in the retina:
not perceptible

5 Example 4 (topical ocular administration)

An isotonic aqueous dispersion has been prepared with the solid lipid nanoparticles (SLNs) prepared according to example 1, having a concentration of SLNs corresponding to 2 mg/ml of gentamicin.

10 Polyvinyl alcohol (M.W. 20,000) has been added to the dispersion as a viscosizing agent, in an amount of 0.2% with respect to the dispersion.

Three rabbits having the characteristics described in example 2 have been used for the experiment.

The administration has been carried out by topically administering 50 μ l of SLNs dispersion into the lower conjunctival sack of one eye of each rabbit.

15 As a control, the same dose of gentamicin has been administered in the same manner to other three rabbits having the same characteristics, by means of a commercial composition denominated Genticol®.

One hour after administration, the following results, which represent the mean values of the concentrations of gentamicin within the eye, have been obtained.

20 (a) Dispersion of SLNs:

- Concentration of gentamicin in the aqueous fluid = 10 μ g/100 μ l
- concentration of gentamicin in the vitreous fluid = 2.76 μ g/100 μ l
- concentration of gentamicin in the retina = 890 ng/100 μ l

(b) Genticol® composition

- 25
- Concentration of gentamicin in the aqueous fluid = 5 μ g/100 μ l
 - Concentration of gentamicin in the vitreous fluid: not perceptible
 - Concentration of gentamicin in the retina: not perceptible.

Example 5 (topical administration)

30 Example 4 has been repeated with the difference that a dose of 200 μ l has been administered.

One hour after administration the following results have been obtained which represent the mean values of the concentrations of gentamicin in the eye.

(a) Dispersion of SLNs:

- concentration of gentamicin in the aqueous fluid = $35\mu\text{g}/100\mu\text{l}$
- concentration of gentamicin in the vitreous fluid = $7.84\mu\text{g}/100\mu\text{l}$
- concentration of gentamicin in the retina = $5.4\mu\text{g}/100\mu\text{l}$

5 (b) Genticol® composition

- concentration of gentamicin in the aqueous fluid = $16\mu\text{g}/100\mu\text{l}$
- concentration of gentamicin in the vitreous fluid = trace
- concentration of gentamicin in the retina = trace.

CLAIMS

1. Use of solid lipidic nanoparticles (SLNs) for the preparation of pharmaceutical compositions suitable for the treatment of ophthalmic diseases by intravenous or topical ocular administration, wherein in said SLNs is incorporated
5 a pharmacologically active substance for the treatment of said diseases.
2. The use according to claim 1, characterised in that said SLNs have a mean diameter comprised between 50 and 400 nm, and a polydispersion comprised of between 0.06 and 0.30.
3. The use according to claim 1, characterised in that said SLNs have an
10 average diameter comprised between 100 and 200 nm and a polydispersion comprised of between 0.10 and 0.20.
4. The use according to claim 1, characterised in that said SLNs have a pharmacologically active substance content comprised of between 0.1 and 7.0%.
5. The use according to claim 1, characterised in that said pharmaceutical
15 compositions suitable for the treatment of ophthalmic diseases by intravenous administration consist essentially of dispersions of said SLNs in isotonic aqueous solutions having a concentration of SLNs comprised between 10 and 250 mg/ml.
6. The use according to claim 1, characterised in that said pharmaceutical
20 compositions suitable for the treatment of ophthalmic diseases by topical ocular administration consist essentially of dispersions of said SLNs in isotonic aqueous solution having a concentration of SLNs comprised between 1.0 and 25% w/v and further containing from 0.1 to 0.4 % of a viscosizing substance.
7. The use according to claim 1, characterised in that said pharmacologically
25 active substance is selected from the group comprising: amphotericin, miconazole, ganciclovir, saquinavir, acyclovir, famciclovir, vidarabine, idoxuridine, β -interferon, paclitaxel, methotrexate, doxorubicin, angiopoietin 1, diclophenac, indomethacin, ketorolac, piroxicam, flurbiprofen, dexamethasone, triamcinolone, hydrocortisone, fluorometholone, rimexolone, timolol, betaxolol and acetazolamide.
8. The use according to claim 1, characterised in that said SLNs are prepared by a
30 process wherein:
 - a) a molten lipid substance containing a drug or its complex is mixed with a mixture comprising water, a surfactant, a cosurfactant and optionally a counterion

of the drug, pre-warmed to a temperature at least equal to the melting temperature of said lipid substance, thus obtaining a microemulsion having a temperature at least equal to the melting temperature of said lipid substance;

b) the microemulsion obtained in step a) is dispersed in water or in an aqueous medium cooled to a temperature comprised between 2 and 5 °C, thus obtaining a dispersion of solid lipidic nanoparticles incorporating the drug;

c) the dispersion obtained in step b) is washed with water or with an aqueous medium by diafiltration with the practically total elimination of the surfactant and the cosurfactant;

d) the dispersion obtained in step c) is dried by lyophilisation or by spray drying or by evaporation, thus obtaining the solid lipid nanoparticles (SLNs) with the drug incorporated.

9. The use according to claim 8, characterised in that the microemulsion obtained in step a) is added to a mixture comprising water, a surfactant, a cosurfactant and a lipid warmed to a temperature at least equal to the melting temperature of the lipid and the mixture thus obtained is dispersed in water or in an aqueous medium cooled to a temperature comprised of between 2 and 5°C.

10. The use according to claim 8, characterised in that at the end of step a) a substance suitable for stabilising the SLNs is added selected from the group comprising dipalmitoyl phosphatidyl ethanolamine-PEG, diacyl phosphatidyl ethanolamine-PEG (PEG M. W. 750-2000) and fatty acids pegylated with PEG-methylethers (PEG M. W. 750-2000).

11. A therapeutic method for the treatment of ophthalmic diseases comprising the intravenous or topical ocular administration of a therapeutically effective amount of a pharmaceutical composition comprising solid lipidic nanoparticles containing a pharmacologically active substance for the treatment of said ophthalmic diseases.

12. The therapeutic method according to claim 11, characterised in that the dosage for intravenous administration is an amount of said composition containing to 0.01-5.0 milligrams of active substance per kilogram of body weight.

13. The therapeutic method according to claim 11, characterised in that the dosage for topical ocular administration is an amount of said composition containing to 0.01-5.0 milligrams of active substance for each eye.

14. A pharmaceutical composition suitable for the treatment of ophthalmic diseases by intravenous or topical ocular administration, consisting essentially of an isotonic aqueous dispersion of solid lipid nanoparticles (SLNs) having a mean diameter comprised between 50 and 400 nm and polydispersion comprised
5 between 0.06 and 0.30, a pharmacologically active substance for the treatment of said diseases being incorporated within said SLNs.

15. The pharmaceutical composition according to claim 14, characterised in that said aqueous dispersion contains a viscosizing substance.

16. The composition according to claim 14, characterised in that said SLNs have a
10 mean diameter comprised between 100 and 200 nm and polydispersion comprised between 0.10 and 0.20.

17. The composition according to claim 14, characterised in that for the intravenous administration, said isotonic aqueous dispersion has a concentration of SLNs comprised of between 10 and 250 mg/ml.

15 18. The composition according to claim 14, characterised in that for the topical ocular administration, said isotonic aqueous dispersion has a concentration of SLNs comprised between 1 and 25% w/v and contains from 0.1 to 0.4% of a viscosizing substance.

19. The composition according to claim 14, characterised in that said SLNs have a
20 pharmacologically active substance content comprised between 0.1 and 7.0%:

20. The composition according to claim 14, characterised in that said pharmacologically active substance is selected from the group comprising: amphotericin, miconazole, ganciclovir, saquinavir, acyclovir, famciclovir, vidarabine, idoxuridine, β -interferon, paclitaxel, methotrexate, doxorubicin,
25 angiopoietin 1, diclophenac, indomethacin, ketorolac, piroxicam, flurbiprofen, dexamethasone, triamcinolone, hydrocortisone, fluorometholone, rimexolone, timolol, betaxolol e acetazolamide.

21. Compositions according to claim 14, characterised in that the lipid of said SLNs is selected from the group comprising trilaurine, tricaprilol, tristearine, tripalmitine,
30 capric/caprylic triglycerides, dipalmitine, distearine, glyceryl monostearate, glyceryl palmitostearate, cetylic alcohol, stearyl alcohol, fatty acids having C10-C22 chains, cholesteryl hemisuccinate, cholesteryl butyrate and cholesteryl palmitate.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039351 A3

(51) International Patent Classification⁷: A61K 9/00, 9/107

(21) International Application Number:
PCT/EP2003/012180

(22) International Filing Date: 31 October 2003 (31.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2002A002323 31 October 2002 (31.10.2002) IT

(71) Applicants and

(72) Inventors: GASCO, Maria, Rosa [IT/IT]; Lungo Po
Antonelli, 207, I-10153 Torino (IT). ZARA, Gian, Paolo
[IT/IT]; Corso Trapani, 207, I-10100 Torino (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SAETTONI, Marco,
Fabrizio [IT/IT]; Via G. Giusti, 24, I-55049 Viareggio (IT).

(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi
S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,

CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
8 July 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 2004/039351 A3

(54) Title: PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THE TREATMENT OF OPHTHALMIC DISEASES

(57) Abstract: Pharmaceutical compositions for the treatment of ophthalmic diseases, suitable for topical ocular administration and for systemic administration, comprising solid lipid nanoparticles (SLNs) with a mean diameter comprised between 50 and 400 nm wherein, within said nanoparticles, a pharmacologically active substance for the specific ophthalmic treatment is incorporated.

INTERNATIONAL SEARCH REPORT

PCT/EP 03/12180

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/00 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 662 932 A (AMSELEM SHIMON ET AL) 2 September 1997 (1997-09-02) column 2, line 29 -column 3, line 3 column 3, line 24,25 column 4, line 49-55 column 10, line 8-40 column 11, line 35-49 examples 6,13,16-18; table 1	1-21
X	EP 0 437 368 A (MERCK SHARP & DOHME) 17 July 1991 (1991-07-17) page 2, line 9-13 page 3, line 39-46 example 1; tables 1-3	1-21

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

4 May 2004

Date of mailing of the international search report

17/05/2004

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Vermeulen, S

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/12180

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. . .
X	GASCO M. R.: "Solid lipid nanospheres form warm micro-emulsions" PHARMACEUTICAL TECHNOLOGY EUROPE, vol. 9, no. 11, 1997, pages 52-58, XP009030038 page 53, column 1-2 page 56, column 3 -page 57, column 1	1-21
X	CAVALLI ROBERTA ET AL: "Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin" INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON), vol. 238, no. 1-2, 15 May 2002 (2002-05-15), pages 241-245, XP002278435 ISSN: 0378-5173 figure 1; tables 1-3	1-21
X	KOMATSU A ET AL: "Application of lipid microsphere drug delivery system to steroidal ophthalmic preparation." JAPANESE JOURNAL OF OPHTHALMOLOGY. JAPAN 1988, vol. 32, no. 1, 1988, pages 41-43, XP009029506 ISSN: 0021-5155 page 43; table 1	1-21
X	US 6 419 949 B1 (GASCO MARIA ROSA) 16 July 2002 (2002-07-16) column 2, line 10-67 claims 1,6; example 3	14-21
X	WO 99/39700 A (COCEANI NICOLETTA ; DEL CURTO MARIA DORLY (IT); ESPOSITO PIERANDREA) 12 August 1999 (1999-08-12) page 3, line 22-25 page 5, line 18 -page 6, line 21 page 9, line 10-25 page 13, line 7-17 example 35	14-21

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 03/12180

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claims 11-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 03/12180

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5662932	A	02-09-1997	US 5576016 A	19-11-1996
			AT 198040 T	15-12-2000
			AU 6916494 A	12-12-1994
			AU 676921 B2	27-03-1997
			AU 6948094 A	12-12-1994
			CA 2162993 A1	24-11-1994
			DE 69426418 D1	18-01-2001
			DE 69426418 T2	10-05-2001
			EP 0702552 A1	27-03-1996
			IL 109641 A	29-02-2000
			JP 8511245 T	26-11-1996
			WO 9426252 A1	24-11-1994
			WO 9426255 A1	24-11-1994
			US 5716637 A	10-02-1998
EP 0437368	A	17-07-1991	FR 2657018 A1	19-07-1991
			CA 2034025 A1	13-07-1991
			DE 69101243 D1	07-04-1994
			DE 69101243 T2	04-08-1994
			EP 0437368 A1	17-07-1991
			JP 3238715 B2	17-12-2001
			JP 4210910 A	03-08-1992
			US 5326761 A	05-07-1994
US 6419949	B1	16-07-2002	IT MI972663 A1	01-06-1999
			AU 2155199 A	16-06-1999
			EP 1071408 A1	31-01-2001
			WO 9927918 A1	10-06-1999
WO 9939700	A	12-08-1999	IT MI980234 A1	06-08-1999
			AU 747129 B2	09-05-2002
			AU 2723899 A	23-08-1999
			BR 9907683 A	14-11-2000
			CA 2319565 A1	12-08-1999
			WO 9939700 A1	12-08-1999
			EP 1051160 A1	15-11-2000
			JP 2002502813 T	29-01-2002